ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

ANTX AN2 Therapeutics Inc

2.56
0.02 (0.79%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
AN2 Therapeutics Inc ANTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.02 0.79% 2.56 23:00:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.56 2.50 2.67 2.56 2.54
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
28/3/202415:10BWAN2 Therapeutics Reports Fourth Quarter and Full Year 2023..
13/2/202416:11EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202406:01EDGAR2Form 8-K - Current report
12/2/202405:45BWAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase..
30/1/202415:10BWAN2 Therapeutics to Present at Oppenheimer Healthcare Life..
18/1/202417:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202416:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202418:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202417:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202417:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:45EDGAR2Form 144 - Report of proposed sale of securities
02/1/202415:36EDGAR2Form 144 - Report of proposed sale of securities
16/11/202317:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:10EDGAR2Form 8-K - Current report
09/11/202315:05BWAN2 Therapeutics Reports Third Quarter 2023 Financial..
06/11/202306:00BWAN2 Therapeutics to Present at Upcoming Investor Conferences
18/10/202306:00BWAN2 Therapeutics Signs License Agreement with the University..
10/10/202323:01BWAN2 Therapeutics to Present New Data for Epetraborole at..
03/10/202318:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202315:10EDGAR2Form 144 - Report of proposed sale of securities
29/9/202316:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202315:11EDGAR2Form 144 - Report of proposed sale of securities
26/9/202306:00BWAN2 Therapeutics Signs Grant Agreement to Discover Novel,..
15/9/202316:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/9/202307:00EDGAR2Form 8-K - Current report
13/9/202306:00BWAN2 Therapeutics commences Phase 3 Part of Phase 2/3..
08/9/202315:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202315:14EDGAR2Form 144 - Report of proposed sale of securities
16/8/202315:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/8/202315:47EDGAR2Form 8-K - Current report
15/8/202321:42BWAN2 Therapeutics Announces Pricing of $70.0 Million..
10/8/202315:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:18EDGAR2Form 8-K - Current report
10/8/202315:10BWAN2 Therapeutics Reports Second Quarter 2023 Financial..
25/5/202315:10BWAN2 Therapeutics to Present at Jefferies Healthcare..
11/5/202315:10BWAN2 Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock